Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

BioArctic AB (BRCTF) reports significant licensing deals and growing market demand, while navigating regulatory challenges and increased expenses.

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

The assay for a particular abnormal form of the protein alpha-synuclein – known as αSyn-SAA – could also be used to diagnose people with Parkinson’s more quickly, help identify the best ...

At the end of 2021, for example, Novartis paid $150 million upfront for rights to an orally-active alpha-synuclein candidate in phase 2 development at UCB in a deal that could be worth $1.5 billion.

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Dementia with Lewy bodies (DLB) is caused by a build-up of an abnormal protein called alpha-synuclein, which clumps together to form Lewy bodies in the brain. It can have symptoms similar to those ...

Seize the opportunity to connect with pioneers like Sir John Hardy and Prof Claudio Soto, delve into alpha-synuclein genetics, navigate the intricate pathways of MSA with experts such as Prof Henry ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...